Table D2Ranking of research priorities using average Likert scale score

RankResearch area
1Impact of comorbidities (such as hypertension, CHF with or without preserved LV function, diabetes, peripheral arterial disease, chronic kidney disease, prior coronary revascularization; single-vs. multi-vessel coronary artery disease) on ACEI/ARB effectiveness or harms in patients with stable IHD
2The impact of ACEI/ARB in patients with stable IHD on progression of renal insufficiency or development of dialysis dependence
2The impact of ACEI/ARB in patients with stable IHD on utilization and cost of therapy
3Impact of demographic differences (such as age, race, sex) on ACEI/ARB effectiveness or harms in patients with stable IHD
3Impact of concurrent medications (such as antiplatelet agents, lipid-lowering medications, other antihypertensives) on ACEI/ARB effectiveness or harms in patients with stable IHD
3The benefit of ACEIs/ARBs relative to alternative medication classes (calcium channel blocker, diuretic, or beta-blocker) with respect to their effectiveness or harms in patients with stable IHD
3Strategies to enhance greater evidence-based use of ACEIs/ARBs
3The impact of ACEI/ARB in patients with stable IHD on cardiovascular outcomes (such as cardiovascular death, nonfatal MI, CVA, hospitalization for CHF, and surrogates such as blood pressure control, measures of atherosclerosis, etc.)
3The impact of ACEI/ARB in patients with stable IHD on incidence of new diagnoses (such as diabetes, atrial fibrillation, CHF with or without preserved LV function)
4Impact of genetic differences (such as ACE or angiotensin II receptor gene polymorphisms) on ACEI/ARB effectiveness or harms in patients with stable IHD
4The impact of ACEI/ARB adherence (including differential adherence within and between medication classes) on their effectiveness or harms in patients with stable IHD
4The impact of ACEI/ARB in patients with stable IHD on patient quality of life
5Impact of the dose response (impact of medication dose or dosing interval) of ACEIs and ARBs on their effectiveness or harms in patients with stable IHD
5Impact of class effect (impact of differences between specific agents within each class) of ACEIs and ARBs on their effectiveness or harms in patients with stable IHD
5The impact of ACEI/ARB in patients with stable IHD on development of nonangioedema adverse effects (such as hypotensive symptoms, cough, syncope, diarrhea, renal insufficiency, hyperkalemia)
6The impact of ACEI/ARB in patients with stable IHD on development of angioedema

Abbreviations in Table D2: ACEI(s) = angiotensin-converting enzyme inhibitor(s), ARB(s) = angiotensin II receptor blocker(s)/antagonist(s), CHF = congestive heart failure, CVA = cerebrovascular accident, IHD = ischemic heart disease, LV = left ventricular, MI = myocardial infarction, PICO = population, interventions, comparators of interest, and outcomes

From: Appendix D, Results of Prioritization Exercises

Cover of Future Research Needs for Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease
Future Research Needs for Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease: Identification of Future Research Needs from Comparative Effectiveness Review No. 18 [Internet].
Future Research Needs Papers, No. 8.
Sanders GD, Powers B, Crowley M, et al.
Copyright Notice

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.